180 Life Sciences Corp. - ATNF STOCK NEWS

180 Life Sciences Corp. (NASDAQ: ATNF) has successfully collected and submitted all patient data from its Phase 2b clinical trial for Dupuytren’s disease, conducted in partnership with the University of Oxford. The trial involved 181 patients and analyzed the efficacy of adalimumab, administered over a series of injections. Despite delays due to the COVID-19 pandemic, data analysis is underway, with results expected to be released in Q4 2021. This trial addresses a significant medical need, as no current approved therapies exist for early-stage Dupuytren’s disease, potentially impacting patient quality of life.

180 Life Sciences Corp. (NASDAQ: ATNF) announced that it received a notification from Nasdaq regarding non-compliance with Listing Rule 5250(c)(1) due to the pending filing of its 2020 Form 10-K. The letter does not immediately impact trading on Nasdaq. The company is currently addressing delays in financial statements following amended filings for its predecessor and a recent SEC statement on warrants. 180 Life Sciences has until June 15, 2021, to file the 10-K and may seek a plan to regain compliance if delayed further, risking potential delisting.

180 Life Sciences Corp. (NASDAQ: ATNF) announced that Dr. Lynn Williams received the International Dupuytren Award 2021 for her research published in 2020, identifying collagen VI as a target in fibrotic diseases. This research, sponsored by 180 Life Sciences, is now the foundation of their preclinical studies aimed at developing new therapies for fibrosis. CEO Dr. James Woody highlighted the significance of this award-winning work in providing insights into potential therapeutic targets.

180 Life Sciences Corp. (NASDAQ: ATNF) has announced a new broadcast titled, “Controlling Inflammation to Stop Disease.” The company's research focuses on anti-TNF antibodies for autoimmune inflammatory diseases, suggesting significant market growth potential as new uses are identified. Ongoing clinical trials aim to address various disorders linked to inflammation. Collaborating with renowned institutions, 180 Life Sciences seeks to innovate treatments for unmet medical needs in inflammatory diseases. The company's lead program is currently in phase 2b/3 trials.

180 Life Sciences Corp. (NASDAQ: ATNF) has been featured in a NetworkNewsWire editorial titled "Controlling Inflammation to Stop Disease." This editorial highlights the significant link between inflammation and various health issues, which account for over 50% of global deaths. 180 Life Sciences is at the forefront of developing anti-inflammatory drugs, with its lead program in phase 2b/3 trials. The company is leveraging expertise from prestigious institutions like Oxford University and Stanford to create innovative therapies targeting unmet needs in inflammatory diseases, fibrosis, and pain.

180 Life Sciences Corp (NASDAQ: ATNF) outlines progress in a letter to stockholders from CEO Dr. James Woody. The company has successfully restated prior financials, completed an $11.7 million private placement, and reduced convertible debt from over $5 million to $316,000. They are adding independent directors to comply with NASDAQ requirements and aim to expedite clinical trials funded by grants. The pipeline includes a Phase 2b/3 trial for Dupuytren's contracture with expected results in the second half of 2021, targeting a market of over 22 million people in the US and EU.

180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology firm, announced its participation in the Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. CEO Dr. James Woody will engage in one-on-one meetings with investors. The company focuses on innovative drug development targeting inflammatory diseases, fibrosis, and pain, with its lead program currently in Phase 2b/3 trials.

180 Life Sciences Corp. (NASDAQ: ATNF) announced the closing of a private placement of 2,564,000 shares and warrants, raising approximately $11.7 million. The shares are priced at $4.55 each, with warrants exercisable at $5.00. Proceeds will support corporate purposes, working capital, and drug development programs.

Maxim Group LLC was the sole placement agent for this transaction. The securities offered were only available to accredited investors and remain unregistered under the Securities Act of 1933.

180 Life Sciences Corp. (NASDAQ: ATNF) announced a private placement to raise approximately $11.7 million by issuing 2,564,000 shares of common stock at a price of $4.55 each, along with warrants. The exercise price for the warrants is $5.00, and they will expire in five years. Closing is expected on February 23, 2021. The offering targets accredited investors and includes a commitment to file registration statements with the SEC for resale of the shares and warrants.